Pfizer (PFE) Stock Looks Above Fair Value As 30% Run Continues

Pfizer has delivered a solid 1 year return, yet the question many investors are circling is whether that share price now lines up with what its earnings can support. With vaccine headlines and deal activity back in the news, the issue is whether the current valuation fairly reflects the profit engine behind the story. The stock has returned 29.7% over the past year, which puts real pressure on the earnings picture to justify the higher price investors are paying today. Fresh data on Pfizer's...